- Open Access
Pulmonary bacterial pathogens in cystic fibrosis patients and antibiotic therapy: a tool for the health workers
International Archives of Medicinevolume 1, Article number: 24 (2008)
Cystic fibrosis is the most common and best known genetic disease involving a defect in transepithelial Cl- transport by mutations in the CF gene on chromosome 7, which codes for the cystic fibrosis transmembrane conductance regulator protein (CFTR). The most serious symptoms are observed in the lungs, augmenting the risk of bacterial infection. The objective of this review was to describe the bacterial pathogens colonizing patients with cystic fibrosis. A systematic search was conducted using the international bibliographic databanks SCIELO, HIGHWIRE, PUBMED, SCIRUS and LILACS to provide a useful and practical review for healthcare workers to make them aware of these microorganisms. Today, B. cepacia, P. aeruginosa and S. aureus are the most important infectious agents in cystic fibrosis patients. However, healthcare professionals must pay attention to emerging infectious agents in these patients, because they represent a potentially serious future problem. Therefore, these pathogens should be pointed out as a risk to these patients, and hospitals all over the world must be prepared to detect and combat these bacteria.
Cystic fibrosis (CF) is the most common autosomal genetic disease in North America, affecting 1:2000 Caucasian individuals . This disease is caused by mutations affecting the cystic fibrosis conductance regulator protein (CFTR) and is characterized by chronic lung malfunction, pancreatic insufficiency and high levels of chloride in sweat. Its high mortality index is evident when lung and spleen are affected, but other organs can also be affected. The persons affected die by progressive bronchiectasis and chronic respiratory insufficiency [2, 3]. This disease affects persons without distinction of age or sex but can be asymptomatic in a great number of cases . Failure of innate defense mechanisms and the lack of mucocilliary clearance in the airways stimulate primary and recurrent bacterial infections, blockage of airways, inflammation and chronic bacterial infections [4, 5].
During the first decade of life of CF patients, Staphylococcus aureus and Hemophilus influenzae are the most common bacteria isolated from the sputum, but in the second and third decade of life, Pseudomonas aeruginosa is the prevalent bacteria. In Germany, analysis of the sputum from CF patients during a period of 12 months showed the presence of P. aeruginosa in 50% of these individuals, S. aureus in 63.3%, Haemophilus influenzae in 16.6%, Stenotrophomonas maltophilia in 15% and nontuberculous Mycobacteria (NTM) in 13.3% .
Due to this succession of bacterial populations in CF patients and due to the importance of these pathogens in prognosis, the objective of this article was to review and identify known and emerging bacterial pathogens associated with pulmonary problems and involved with cystic fibrosis. For this objective, a systematic search was conducted using the international bibliographic databanks SCIELO, HIGHWIRE, PUBMED, SCIRUS and LILACS. The uniterms Cystic fibrosis, infection and antibiotic therapy were used in a retrospective search between 1990 to 2007. Any articles with this theme, reporting bacterial pathogen associated with CF patients with no distinction of sex and age were selected and only the articles describing pathogens and the antibiotic therapy were really used.
Bacterial pathogens associated with pulmonary risk
The nontuberculous Mycobacteria (NTM) are a group of microorganisms that is very common in chronic pulmonary diseases. The increase in the life expectancy of CF patients has also increased the prevalence of Mycobacteria in the CF population . The clinical impact of these microorganisms in CF patients is unclear, because Oliver et al.  found that CF patients infected with NTM, observed for 15 months, did not show a decline in respiratory function. These microorganisms were isolated from older CF patients, all of them with perfect respiratory function, and were associated with a high frequency of S. aureus and a low one of P. aeruginosa when compared with patients without NTM, indicating that the presence of these bacteria may be taken as a good prognostic sign .
The most common NTM infecting CF patients are Mycobacterium abscessus, Mycobacterium avium, and Mycobacterium intracellulare , but Sermet-Gaudelus et al.  identified other NTM from CF patients, including M. fortuitum, M. gordonae and M. kansasii. Today, the NTM more likely associated with the disease is Mycobacterium abscessus . The identification of the causal species of NTM is essential and requires genetic techniques . Treatment depends on the mycobacterial species. For M. avium, combined therapy with rifampicin, clarythromycin and ethambutol must be extended 12 months after negativation. M. abscessus infection is particularly resistant to therapy. Usual treatment is a one month course of intravenous imipenem or cefoxitin plus amikacin followed by oral clarithromicin plus ethambutol for at least 12 months after negativation. In case of local lesions, surgery is an option .
Usually, this is the first pathogen to infect and colonize the airways of CF patients, being the most common pathogen . This microorganism is prevalent in children and may cause epithelial damage, opening the way to the adherence of other pathogens such as Pseudomonas aeruginosa . However, other studies indicate that S. aureus is a co-infective pathogen associated with P. aeruginosa. Together, the inflammatory process is more intense due the additive effect of these two pathogens . Before the use of antibiotics in the treatment of infections, S. aureus was the causative agent of several deaths in children with CF. Today, this risk is not so serious, but CF patients not given the correct antibiotic therapy show a higher prevalence of S. aureus in the nasal epithelium when compared to treated patients . About the prevalence of this pathogen, the same strain of S. aureus remains in the patient for 1–2 years .
Methicillin-resistant S. aureus (MRSA) has become a major nosocomial pathogen with a progressive increase in prevalence also in CF populations. The acquisition of MRSA occurred only in adulthood . In Europe, the spread of MRSA varies widely among centers, ranging from 5 to 14% . MRSA is a major pathogen in the hospital setting causing serious infections that usually present multiresistance to many antibiotics. Moreover, the increased frequency of this organism in the community, especially with carriage of virulence factors, including the presence of the virulence marker pvl, is a matter of concern [20, 21].
Small colony variants (SCVs) of S. aureus constitute a bacterial population with distinctive phenotypic traits of S. aureus populations from CF patients . These populations are involved with the colonization of older patients , but Sadowska et al.  isolated these strains from children between 1.5 and 9 years old with a SVR prevalence of 31.7%.
P. aeruginosa is an oxidase-positive Gram-negative motile rod . Vonberg & Gastmeier  showed that this bacterium colonizes CF patients in more than 50% of cases. This bacterium is a part of the normal microbial population of the respiratory tract, where it is an opportunistic pathogen in CF patients. This is more prevalent in adult CF patients, as infection has been shown in 20% CF patients 0–2 years old while in 81% in adult groups (>18 years old) . Aaron et al.  showed that all CF patients with chronic infections and older than 16 years are infected with P. aeruginosa, but Burns et al.  found that 97.5% of children had P. aeruginosa. The capacity of this bacterium to develop biofilm is a characteristic that allows it to survive for very long periods in the lungs of CF patients .
Isolated from P. aeruginosa can be differentiated in terms of its morphotypes, including mucoid, not mucoid and those with biofilm, which vary their patterns of susceptibility to antibiotics. This differentiation causes several problems in the treatment, because is necessary identify the morphotype to choose the treatment strategy [31, 32].
Burkholderia cepacia complex (BCC) is a complex of Gram-negative rod, aerobic, mesophilic and chemoorganotrophic . This is a bacterial complex with nine genomic species (genomovars) [34, 35]: genomovar I (B. cepacia), II (B. multivorans), III (B. cenocepacia), IV (B. stabilis), V (B. vietnamiensis), VI (B. dolosa), VII (B. ambifaria), VIII (B. anthina), IX (B. pyrrocinia) [35, 36].
Infected CF patients show high levels of BCC in the salivary fluid, indicating the possibility of indirect transmission by kissing and sexual contact , but the transmission rates, prognosis and mortality are distinctly characteristic for each genomovar, as the treatment strategies[33, 37]. Because the difficulties in the culture and identification of genomovar, this is one of the most important opportunistic bacterial pathogens of CF patients [38, 39]. Other bacteria the same genus Burkholderia, as Burkholderia gladioli and Burkholderia pseudomallei, which are distinct from the Burkholderia cepacia complex have also been reported in patients with cystic fibrosis [40–42]. Members of B. cepacia complex are very resistant to antibiotic therapy because its genome is very plastic and suffers several mutations and adapts itself, making it a hard challenge for treatment. Its resistance is mainly due the production of enzymes with capacity to inactivate the substances used in the treatment . By this fact., the accuracy and fast detection of this bacterium are essential to evaluate risks, prognostics and epidemiology of cystic fibrosis .
This bacterium is a Gram-negative rod, anaerobic, motile, oxidase and catalase positive and lactose non-fermentative. It is usually distributed in the environment, but can be a human pathogen causing bacteremia, meningitis and pneumonia . This is a pathogen with a growing incidence in CF patients and a high coinfection rate with P. aeruginosa [45, 46].
Coenye et al.  in 2002 isolated 8 strains from airway secretions of CF patients in the United States, that were identified as a new genus called Inquilinus, belonging to α-proteobacteria and further identified as I. limosus. This bacterium is a mesophilic Gram-negative rod, non-spore forming. Due to its recent characterization, we have little knowledge about its natural habitat, prevalence and pathogenicity, but CF patients infected with this bacterium have been identified in hospitals in France, Spain and Germany [48, 49].
These bacteria are Gram-negative and non-fermentative rods, and little is known about the natural occurrence and the pathogenicity of bacteria from the genus Ralstonia, mainly due to their difficult identification, where they are usually misidentified as P. fluorescens or a member of the Burkholderia cepacia complex [50–54].
Reports indicate a low prevalence of pathogen from this genus in CF patients, but Coenye et al.  showed the permanence of this pathogen in the sputum of CF patients for more than 20 months.
This is a Gram-negative and non-fermentative bacterium that over the years has shown a growing isolation frequency among CF patients, representing a possible emerging pathogen in these patients [55, 56]. Atkinson et al.  analyzed sputum cultures from 2 adult CF patients (30 and 36 years old, respectively), and found both colonized by this bacteria and coinfected with P. aeruginosa. This finding is very important due to the fact that these patients are first infected with P. aeruginosa, indicating that the latter pathogen may act as a starting point for P. apista infection.
This microorganism is considered a transient pathogen in CF patients , mainly isolated from young CF patients . The incidence is 5.5% in CF patients 12 and younger, but in children without the disease the frequency is 50% .
This is a Gram-negative and non-fermentative rod that is frequently isolated from hospitals [61, 62]. S. maltophilia is a pathogen of CF patients with a very constant incidence . Goss et al.  observed that patients with S. maltophilia were older, showing a high rate of prior co-infection with P. aeruginosa and B. cepacia, but the prevalence of this pathogen in CF patients has been growing in the last years .
This bacterium usually infects younger CF patients. In Brazil, 20.4% of CF children between 6 and 12 years old are infected by H. influenzae . This bacterium undergoes hyper-mutation, which can be related to its resistance to antibiotics, making treatment more difficult .
This is a Gram-negative coccobacillus, non spore-forming, strictly anaerobic, and catalase and coagulase positive . This bacterium is part of the microbiota of the upper respiratory tract of many animals . Magalhães et al. , reported the presence of it in a 27- year-old CF patient associated with S. aureus, which can be a potential zoonotic infectious agent, aggravating the CF patient situation.
Cystic fibrosis is characterized by chronic pulmonary infection with acute pulmonary exacerbation (APEs), where antibiotic therapy is necessary against opportunistic infections .
Previous studies have indicated that the presence of mucoidal P. aeruginosa was the most important risk factor for pulmonary deterioration [70, 71]. By this fact, several article indicating method to control de colonizing pathogens in CF patients use P. aeruginosa as a microbial marker.
Gentamicin and tobramycin are recognized as standard antibiotics for the treatment of CF patients infected with Pseudomonas aeruginosa. Mulheran et al.  observed a higher utilization of gentamicin and tobramycin by pediatric patients and adults respectively. However, the authors make note of the greater cochleotoxic risk associated with gentamicin. Depending on the administration and dose used, tobramycin can be more or less efficient . When this drug was used in a liposomal formulation and delivered as an aerosol, the drug bioavailability in pulmonary tissue and its effectiveness enhance [74, 75].
Tests with animals have shown the augmentation of the amykacin concentration in the lung against Pseudomonas aeruginosa, when the drug is administered by ultrasonic nebulization or intravenously, but these levels decrease after the second administration .
Antibiotic combinations against P aeruginosa, such as the use of polymyxins combined with a β-lactamic are useful in antipseudomonial therapy, as shown in the work of Dong & Chung-Dar .
Azithromycin displays interesting therapeutic results in the treatment of CF patients infected with P aeruginosa. Wagner et al.  reported that azithromycin inhibits 80% of protein synthesis in P aeruginosa PAO1, affecting bacterial growth and the expression/exportation of products that stimulates the immune system such as pyocyanin.
Other point of discussion is the objective of the treatment of P aeruginosa infection: total eradication, using heavy doses of antibiotics with adverse symptoms, or the management of the infection, with a higher risk to develop the resistance? Few years ago, the eradication of chronic P. aeruginosa infection was considered impossible , but Ho et al.  e Pitt et al.  showed that new populations of P. aeruginosa (after eradication) were different of the first ones and more sensitive to the antibiotics, showing that persistent populations of P. aeruginosa in the airway would increase the antibiotic resistance with time because of prolonged exposure to antibiotics, as in the case of management, indicating the eradication as the most interesting strategy.
For other microorganisms such as B. cepacia, commonly resistant to several antimicrobial drugs used by CF patients, the better treatment choice is a drug combination. Combinations of two antibiotics from different classes such as meropenem-minocycline, meropenem-amikacin and meropenem-ceftazidime or three different antibiotics such as tobramycin, meropene and an additional antibiotic were more effective than the use of any antibiotic alone . Similar results were observed against P. aeruginosa by Dong et al.  who showed that the better treatment is the combination of meropenem/tobramicin or ceftazidime/tobramicin.
However, new therapeutic perspectives are needed, such as from the work of Zhang et al.  who evaluated the in vitro effectiveness of 150 antimicrobial peptides in multidrug resistant strains of P. aeruginosa, Stenotrophomonas maltophilia, Achromobacter xylosoxidans and S. aureus. A better activity was observed for several peptides compared to most of the antibiotics used in the clinic. Similar results were obtained by Etienne et al.  who used defensins and observed a drastic reduction in bacterial growth.
These reports indicate the necessity for more research into the discovery and rational design of new antibacterial drugs that will be more efficient in combating infections in cystic fibrosis patients. However, the use must be well defined. Our search indicates that the combination of 2 or more antibiotics may represent an interesting alternative in the CF treatment, colonized for any bacterial pathogen.
Other point of interest is the indication of aerosolized and biofilm-inhibitory drugs may control and avoid the colonization of the respiratory tract by several pathogens cited in this study. Maybe, using this several approaches, we will maximize the control of the colonizers and the infections that affect the CF patients.
Several factors affect transmission, such as the type of bacterial strain, the immune state of the patient and the use of contaminated medical equipment. Therefore, all CF patients infected or colonized the major pathogens cited in this article must be isolated in a single room because they represent sources for nosocomial transmission of the microorganism to other patients during the treatment [17, 55].
Although the epidemiology of bacterial pathogens in CF patients has become more complex, the life expectancy of these patients continues to increase. This has led to a better control of the transmission of these pathogens by the separation of adults and children with CF in different treatment centers. Furthermore, the utilization of basic preventive guidelines (hand washing and use of masks, gloves and protectors), combined with disinfection techniques to be applied at home or hospital make control easier. These precautions help reduce the impact of infections in CF patients. In addition, educational programs to support administrative measures, guidelines for the control of nosocomial infections and the assistance to healthcare workers and to the families of the patients to show the importance of these measures are essential tools for blocking the transmission of these bacterial pathogens to CF patients.
Chu KK, Davidson DJ, Halsey TK, Chung JW, Speert DP: Differential persistence among genomovars of the Burkholderia cepacia complex in a murine model of pulmonary infection. Infect Immun 2002, 70:2715–2720.
Goldman L, Bennett JC: CECIL: Textbook of Medicine. 21 Edition Guanabara Koogan, Rio de Janeiro 2001.
Chaparro C, Maurer J, Gutierrez C, Krajden M, Chan C, Winton T, Keshavjee S, Scavuzzo M, Tullis E, Hutcheon M, Kesten S: Infection with Burkholderia cepacia in cystic fibrosis: Outcome following lung transplantation. Am J Respir Crit Care Med 2001, 163:43–48.
Boucher RC: New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 2004, 23:146–158.
Accurso FJ: Update in cystic fibrosis 2005. Am J Respir Crit Care Med 2006, 173:944–947.
Valenza G, Tappe D, Turnwald D, Frosch M, König C, Hebestreit H, Abele-Horn M: Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J Cyst Fibros 2008,7(2):123–127.
Cullen AR, Cannon CL, Mark EJ, Colin AA:Mycobacterium abscessus Infection in Cystic Fibrosis Colonization or Infection? Am J Respir Crit Care Med 2000, 161:641–645.
Oliver A, Maiz L, Canton R, Escobar H, Baquero F, Gómez-Mampaso E: Nontuberculous mycobacteria in pacients with cystic fibrosis. Clin Infec Dis 2001, 32:1298–1303.
Oliver KN, Weber DJ, Wallace RJ, Escobar H, Baquero F, Gómez-Mampaso E: Nontuberculous mycobacteria I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003, 167:828–34.
Sermet-Gaudelus I, Le Bourgeois ML, Pierre-Audigier C, Offredo C, Guillemot D, Halley S, Akoua-Koffi C, Vincent V, Sivadon-Tardy V, Ferroni A, Berche P, Scheinmann P, Lenoir G, Gaillard JL:Mycobacterium abscessus and Children with Cystic Fibrosis. Emerg Infect Dis 2003, 9:1587–1591.
Jönsson BE, Gilljam M, Lindblad A, Ridell M, Wold AE, Welinder-Olsson C: Molecular Epidemiology of Mycobacterium abscessus , with Focus on Cystic Fibrosis. J Clin Microbiol 2007, 45:1497–1504.
Le Burgeois M, Sermet-Gaudelus I, Catherinot E, Gaillard JL: Mycobactéries atypiques et mucoviscidose. Archiv Pediatr 2005,12(Suppl 2):S117-S121.
Saiman L, Siegel J: Infection control in Cystic Fibrosis. Clin Microbiol Rev 2004, 17:57–71.
Lyczak JB, Cannon CL, Pier GB: Lung Infections Associated with Cystic Fibrosis. Clin Microbiol Rev 2002, 15:94–222.
Sagel SD, Gibson RL, Emerson J, McNamara S, Burns JL, Wagener JS, Ramsey BW: Impact of Pseudomonas and Staphylococcus Infection on Inflammation and Clinical Status in Young Children with Cystic Fibrosis. J Pediatr, in press. doi:10.1016/j.jpeds.2008.08.001.
Goerke C, Kraning K, Stern M, Döring G, Botzenhart K, Wolz C: Molecular epidemiology of community-acquired Staphylococcus aureus in families with and without cystic fribrosis patients. J Infect Dis 2000, 181:984–989.
Branger C, Gardye C, Lambert-Zechovsky N: Persistence of Staphylococcus aureus strains among cystic fibrosis patients over extended periods of time. J Med Microbiolol 1996, 45:294–301.
Spicuzza L, Sciuto C, Vitaliti G, Di Dio G, Leonardi S, La Rosa M: Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients. Eur J Clin Microbiol Infect Dis, in press. DOI 10.1007/s10096–008–0605–4
Campana S, Taccetti G, Ravenni N, Masi I, Audino S, Sisi B, Repetto T, Döring G, Martino M: Molecular epidemiology of Pseudomonas aeruginosa, Burkholderia cepacia complex and methicillin-resistant Staphylococcus aureus in a cystic fibrosis center. J Cyst Fibros 2004, 3:159–163.
Yang JA, Park DW, Sohn JW: Novel PCR-restriction fragment length polymorphism analysis for rapid typing of staphylococcal cassette chromosome mec elements. J Clin Microbiol 2006, 44:236–238.
Tristan A, Bes M, Meugnier H: Global distribution of Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus . Emerg Infect Dis 2007, 13:594–600.
Kahl B, Herrmann M, Everding AS, Koch HG, Becker K, Harms E, Proctor RA, Peters G: Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J Infect Dis 1998, 177:1023–1029.
Vergison A, Denis O, Deplano A, Casimir G, Claeys G, DeBaets F, DeBoeck K, Douat N, Franckx H, Gigi J, Ieven M, Knoop C, Lebeque P, Lebrun F, Malfroot A, Paucquay F, Pierard D, Van Eldere J, Struelens MJ: National survey of molecular epidemiology of Staphylococcus aureus colonization in Belgian cystic fibrosis patients. J Antimicrob Chemother 2007, 59:893–999.
Sadowska B, Bonar A, von Eiff C, Proctor RA, Chmiela M, Rudnicka W, Róźalska B: Characteristics of Staphylococcus aureus , isolated from airways of cystic fibrosis patients, and their small colony variants. FEMS Immunol Med Microbiol 2002, 32:191–197.
Hart CA, Winstanley C: Persistent and aggressive bacteria in the lungs of cystic fibrosis children. Br Med Bull 2002, 61:81–96.
Vornberg RP, Gastmeier P: Isolation of Infectious Cystic Fibrosis Patients: Results Of A Systematic Review. Infect Control Hosp Epidemiol 2005, 26:401–409.
Tramper-Stranders GA, Ent CK, Slieker MG, Terheggen-Lagro SW, Teding van Berkhout F, Kimpen JL, Wolfs TF: Diagnostic value of serological tests against Pseudomonas aeruginosa in a large cystic fibrosis population. Thorax 2006, 61:689–693.
Aaron SD, Kottachchi D, Ferris WJ, Vandemheen KL, St Denis ML, Plouffe A, Doucette SP, Saginur R, Chan FT, Ramotar K: Sputum versus bronchoscopy for diagnosis of Pseudomonas aeruginosa biofilms in cystic fibrosis. Eur Respir J 2004, 24:631–637.
Burns JL, Gibson RL, McNamara S, Yim D, Emerson J, Rosenfeld M, Hiatt P, McCoy K, Castile R, Smith AL, Ramsey BW: Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2002, 183:444–452.
Costerton JW: Cystic fibrosis pathogenesis and the role of biofilms in persistent infection. Trends Microbiol 2001, 9:50–52.
Martin DW, Schurr MJ, Mudd MH, Govan JR, Holloway BW, Deretic BW: Mechanism of conversion to mucoid in Pseudomonas aeruginosa infecting cystic fibrosis patients. Proc Nat Acad Sci USA 1993, 90:8377–8381.
Saiman L, Mehar F, Niu WW, Neu HC, Shaw KJ, Miller G, Prince A: Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infects Dis 1996, 23:532–537.
Wallet F, Perez T, Armand S, Wallaert B, Courcol RJ: Pneumonia Due to Bordetella bronchiseptica in a Cystic Fibrosis Patient: 16S rRNA Sequencing for Diagnosis Confirmation. J Clin Microbiol 2002, 40:2300–2301.
Ner Z, Ross LA, Horn MV, Keens TG, MacLaughlin EF, Starnes VA, Woo MS:Bordetella bronchiseptica infection in pediatric lung transplant recipients. Pediatr Transplantation 2003, 7:413–417.
Melo-Coutinho HD:Burkholderia cepacia complex: Virulence characteristics, importance and relationship with cystic fibrosis. Indian J Med Sci 2007, 61:422–429.
LiPuma JJ, Dulaney BJ, McMenamin JD, Whitby PW, Stull TL, Coenye T, Vandamme P: Development of rRNA-based PCR assays for indentification of Burkholderia cepacia complex isolates recovered from cystic fibrosis patients. J Clin Microbiol 1999, 37:3167–3170.
Soni R, Marks G, Henry DA, Robinson M, Moriarty C, Parsons S, Taylor P, Mahenthiralingam E, Speert DP, Bye PT: Effect of Burkholderia cepacia infection in the clinical course of patients with cystic fibrosis: A pilot study in a Sydney clinic. Respirology 2002, 7:241–245.
Vermis K, Coenye T, Lipuma JJ, Mahenthiralingam E, Nelis HJ, Vandamme P: Proposal to accommodate Burkholderia cepacia genomovar VI as Burkholderia dolosa sp. nov. Int J Syst Evol Microbiol 2004, 54:689–691.
Mahenthiralingam E, Vandamme P, Campbell ME, Henry DA, Gravelle AM, Wong LT, Davidson AG, Wilcox PG, Nakielna B, Speert DP: Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: Virulent transmissible strains of genomovar III can replace Burkholderia multivorans . Clin Infect Dis 2001, 33:1469–1475.
Kennedy MP, Coakley RD, Donaldson SH, Aris RM, Hohneker K, Wedd JP, Knowles MR, Gilligan PH, Yankaskas JR: Burkholderia gladioli: Five year experience in a cystic fibrosis and lung transplantation center. J Cyst Fibros 2007, 6:267–273.
O'Carroll M, Kidd T, Coulter C, Smith H, Rose B, Harbour C, Bell S:Burkholderia pseudomallei : another emerging pathogen in cystic fibrosis. Thorax 2003, 58:1087–1091.
Barth AL, Abreu e Silva FA, Hoffmann Vieira M, Zavascki P, Ferreira PAC, Cunha LG Jr., Albano RA, Marques EA: Cystic Fibrosis patient with Burkholderia pseudomallei infection acquired in Brazil. J Clin Microbioly 2007, 45:4077–4080.
Miller MB, Gilligan PH: Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis. J Clin Microbiol 2003, 41:4009–4015.
Liu L, Coenye T, Burns JL, Whitby PW, Stull TL, LiPuma JJ: Ribosomal DNA-Directed PCR for Identification of Achromobacter ( Alcaligenes ) xylosoxidans Recovered from Sputum Samples from Cystic Fibrosis Patients. J Clin Microbiol 2002, 40:1210–1213.
Tan K, Conway SP, Brownlee KG, Etherington C, Peckham DG:Alcaligenes infection in cystic fibrosis. Pediatr Pulmonol 2002, 34:101–104.
Van Daele S, Verhelst R, Claeys G, Verschraegen G, Franckx H, Van Simaey L, de Ganck C, De Baets F, Vaneechoutte M: Shared Genotypes of Achromobacter xylosoxidans Strains Isolated from Patients at a Cystic Fibrosis Rehabilitation Center. J Clin Microbiol 2005, 43:2998–3002.
Coenye T, Goris J, Spilker T, Vandamme P, LiPuma JJ: Characterization of Unusual Bacteria Isolated from Respiratory Secretions of Cystic Fibrosis Patients and Description of Inquilinus limosus gen. nov., sp. nov. J Clin Microbiol 2002, 40:2062–2069.
Chiron R, Marchandin H, Counil F, Jumas-Bilak E, Freydière AM, Bellon G, Husson MO, Turck D, Brémont F, Chabanon G, Segonds C: Clinical and Microbiological Features of Inquilinus sp. Isolates from Five Patients with Cystic Fibrosis. J Clin Microbiol 2005, 43:3938–3943.
Wellinghausen N, Essig A, Sommerburg O:Inquilinus limosus in patients with cystic fibrosis, Germany. Emerg Infect Dis 2005, 11:3390–3397.
Yabuuchi E, Kosako Y, Yano I, Hotta H, Nishiuchi Y: Transfer of two Burkholderia and an Alcaligenes species to Ralstonia gen. nov.: proposal of Ralstonia pickettii (Ralston, Palleroni and Doudouroff 1973) comb. nov., Ralstonia solanacearum (Smith 1896) comb. nov. and Ralstonia eutropha (Davis 1969) comb. nov. Microbiol Immunol 1995, 39:897–904.
Coenye T, Vandamme P, Lipuma JJ: Characterisation of unusual bacteria isolated from CF sputum. Pediatr Pulmonol 2001, 22:297.
Coenye T, Vandamme P, Lipuma JJ: Infection by Ralstonia Species in Cystic Fibrosis Patients: Identification of R. pickettii and R. mannitolilytica by Polymerase Chain Reaction. Emerg Infect Dis 2002, 8:692–696.
Burns JL, Emerson J, Stapp JR, Yim DL, Krzewinski J, Louden L, Ramsey BW, Clausen CR: Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998, 27:158–163.
Ferroni A, Sermet-Gaudelus I, Abachin E, Quesne G, Lenoir G, Berche P, Gaillard JL: Use of 16S rRNA gene sequencing for identification of nonfermenting Gram-negative bacilli recovered from patients attending a single cystic fibrosis center. J Clin Microbiol 2002, 40:3793–3797.
Coenye T, Falsen E, Hoste B, Ohlén M, Goris J, Govan JR, Gillis M, Vandamme P: Description of Pandoraea gen. nov. with Pandoraea apista sp. nov., Pandoraea pulmonicola sp. nov., Pandoraea pnomenusa sp. nov., Pandoraea sputorum sp. nov., and Pandoraea norimbergensis comb. nov. Int J Syst Evol Microbiol 2000, 50:887–99.
Jorgensen IM, Johansen HK, Frederiksen B, Pressler T, Hansen A, Vandamme P, Høiby N, Koch C: Epidemic spread of Pandoraea apista , a new pathogen causing severe lung disease in cystic fibrosis patients. Pediatr Pulmonol 2003, 36:439–446.
Atkinson RM, Lipuma JJ, Rosenbluth DB, Dunne WM Jr: Chronic Colonization with Pandoraea apista in Cystic Fibrosis Patients Determined by Repetitive-Element-Sequence PCR. J Clin Microbiol 2006, 44:833–8336.
Renders N, Verbrugh H, van Belkum A: Dynamics of bacterial colonisation in the respiratory tract of patients with cystic fibrosis. Infect Genet Evol 2001, 1:29–39.
del Campo R, Morosini MI, de la Pedrosa EG, Fenoll A, Muñoz-Almagro C, Máiz L, Baquero F, Cantón R: Population Structure, Antimicrobial Resistance, and Mutation Frequencies of Streptococcus pneumoniae Isolates from Cystic Fibrosis Patients. J Clin Microbiol 2005, 43:2207–2214.
Munõz C, Juncosa T, Gené A, Fortea J, Séculi JL, Latorre C: Microbiological study of the respiratory tract in children with cystic fibrosis. Enferm Infecc Microbiol Clin 1996, 14:142–144.
Denton M, Kerr KG: Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia . Clin Microbiol 1998, 11:57–80.
Goss CH, Otto K, Aitken ML, Rubenfeld GD: Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. Am J Respir Crit Care Med 2002, 166:356–361.
Goss CH, Mayer-Hamblett N, Aitken ML, Rubenfeld GD, Ramsey BW: Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax 2004, 59:955–959.
Bauernfeind A, Emminger G, Horl G, Ott S, Przyklenk B, Weisslein-Pfister C: Bacteriological effects of anti- Pseudomonas aeruginosa chemotherapy in cystic fibrosis. Infection 1987, 15:403–406.
Peltroche-Llacsahuanga H, Haase G, Kentrup H: Persistent airway colonization with Alcaligenes xylosoxidans in two brothers with cystic fibrosis. Eur J Clin Microbiol Infect Dis 1998, 17:132–134.
De Baets F, Schelstraete P, Van Daele S, Haerynck F, Vaneechoutte M:Achromobacter xylosoxidans in cystic fibrosis: Prevalence and clinical relevance. J Cyst Fibros 2007, 6:75–78.
Magalhães M, Britto MCA, Bezerra PGM, Veras A: Prevalence of potentially pathogenic bacteria in respiratory specimens of cystic fibrosis patients from Recife. J Bras Patol Med Lab 2004, 40:223–227.
Román F, Cantón R, Pérez-Vázquez M, Baquero F, Campos J: Dynamics of Long-Term Colonization of Respiratory Tract by Haemophilus influenzae in Cystic Fibrosis Patients Shows a Marked Increase in Hypermutable Strains. J Clin Microbiol 2004, 42:1450–1459.
Ledson MJ, Gallagher MJ, Corkill JE, Hart CA, Walshaw MJ: Cross infection between cystic fibrosis patients colonized with Burkholderia cepacia . Thorax 1998, 53:432–436.
Li Z, Kosorok MR, Farrell PM: Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005, 293:581–588.
Parad RB, Gerard CJ, Zurakowski D, Nichols DP, Pier GB: Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. Infect Immun 1999, 67:4744–4750.
Mulheran M, Degg C, Burr S, Morgan DW, Stableforth DE: Occurrence and Risk of Cochleotoxicity in Cystic Fibrosis Patients Receiving Repeated High-Dose Aminoglycoside Therapy. Antimicrob Agents Chemother 2001, 9:2502–2509.
Coenye T, Lipuma JJ: Multilocus restriction typing: A novel tool for studying global epidemiology of Burkholderia cepacia complex infection in cystic fibrosis. J Infect Dis 2002, 185:1454–1462.
Blumer JL, Saiman L, Konstan MW, Melnick D: The Efficacy and Safety of Meropenem and Tobramycin vs Ceftazidime and Tobramycin in the Treatment of Acute Pulmonary Exacerbations in Patients With Cystic Fibrosis. Chest 2005, 128:2336–2346.
Burkhardt O, Lehmann C, Madabushi R, Kumar V, Derendorf H, Welte T: Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? J Antimicrob Chemother 2006, 58:822–829.
Marier JF, Brazier JL, Lavigne J, Ducharme MP: Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa : a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats. J Antimicrob Chemother 2003, 52:247–252.
Dong HK, Chung-Dar L: Polyamines Increase Antibiotic Susceptibility in Pseudomonas aeruginosa . Antimicrob Agents Chemother 2006, 50:1623–1627.
Wagner T, Soong G, Sokol S, Saiman L, Prince A: Effects of Azithromycin on Clinical Isolates of Pseudomonas aeruginosa From Cystic Fibrosis Patients. Chest 2005, 128:912–919.
Doring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A: Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000, 16:749–767.
Ho AS, Lee TWR, Denton M, Conway SP, Brownlee KG: Regimens for eradicating early Pseudomonas aeruginosa infection in children do not promote antibiotic resistance in this organism. J Cyst Fibros, in press. doi:10.1016/j.jcf.2008.08.001
Pitt TL, Sparrow M, Warner M, Stefanidou M: Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax 2003, 58:794–796.
Zhang L, Parente J, Harris SM: Antimicrobial Peptide Therapeutics for Cystic Fibrosis. Antimicrob Agents Chemother 2005, 49:2921–2927.
Etienne O, Picart C, Taddei C, Haikel Y, Dimarcq JL, Schaaf P, Voegel JC, Ogier JA, Egles C: Multilayer Polyelectrolyte Films Functionalized by Insertion of Defensin: a New Approach to Protection of Implants from Bacterial Colonization. Antimicrob Agents Chemother 2004, 48:3662–3669.
Ratjen F, Doring G: Cystic fibrosis. Lancet 2003, 361:681–689.
Gibson RL, Burns JL, Ramsey BW: Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003, 168:918–951.
The authors declare that they have no competing interests.
VSFS and GFG contributed to conception and design, designed the review, carried out the literature research, and manuscript preparation. HDMC contributed to conception and design, carried out the manuscript editing and manuscript review. All authors read and approved the final manuscript.